Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) appoints outpatient nurses from leading healthcare provider Ascott
- The nurses, trained in R327 DFI treatment, will broaden the company’s diabetic foot infection (DFI) trial patient population
- RCE’s phase one/two trial is assessing the safety and efficacy of R327 as a treatment for patients with mild skin and soft tissue diabetic foot infections
- The company is currently carrying out the largest DFI study in Australia
- Shares in RCE are up 4.46 per cent and trading at 58.5 cents at 1:05 pm AEST
Recce Pharmaceuticals (RCE) has on-boarded outpatient nurses from leading healthcare provider Ascott, broadening the company’s treatable diabetic foot infection (DFI) trial patient population.
For more than 22 years, Ascott has provided clinical experience and expertise across the pharma and healthcare industry.
“We are thrilled to further strengthen our phase one/two clinical trial with the support of Ascott,” Recce CEO James Graham said.
The trial is assessing the safety and efficacy of R327 as a treatment for patients with mild skin and soft tissue diabetic foot infections.
“As the global search for an effective treatment for diabetic foot infections continues, Recce is leading the way by conducting Australia’s largest DFI study,” Mr Graham said.
“The company continues to address unmet medical needs through our portfolio of clinical programs.”
In the United States, treating diabetic foot diseases costs between US$9 billion and 13 billion (A$14 billion and 20 billion) every year. Of these, 14 to 24 per cent of patients with diabetes who develop a foot ulcer require an amputation.
Recce reported that using R327 dosing protocols, Ascott nurses would replicate the same level of care patients receive during on-site visits.
Shares in RCE were up 4.46 per cent and trading at 58.5 cents at 1:05 pm AEST.
